{"schema_version":"secwatch.filing_event.v1","accession":"0001070081-23-000036","form_type":"8-K","ticker":"PTCT","cik":"0001070081","company_name":"PTC THERAPEUTICS, INC.","filed_at":"2023-06-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:37.853032+00:00","generated_at":"2026-06-13T19:42:20.907127+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"PTC Therapeutics reports positive interim Phase 2 data for PTC518 in Huntington's disease","bullets":["Interim data from PIVOT-HD Phase 2 study shows dose-dependent lowering of HTT protein in blood, with mean 30% reduction at 10mg dose.","PTC518 treatment well tolerated; no treatment-related serious adverse events or dose-limiting toxicities reported.","No CSF NfL treatment-related spikes; trend towards lowering of CSF NfL levels after 12 weeks.","Conference call held June 21, 2023 at 8:00 AM EDT to discuss data; slides furnished as Exhibit 99.2."],"urls":{"canonical":"https://secwatch.observer/filing/0001070081-23-000036","json":"https://secwatch.observer/filing/0001070081-23-000036.json","markdown":"https://secwatch.observer/filing/0001070081-23-000036.md","text":"https://secwatch.observer/filing/0001070081-23-000036.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1070081/000107008123000036/0001070081-23-000036-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1070081/000107008123000036/tmb-20230621x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T19:42:20.907127+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}